Numerous meta-analyses have shown that, for mild to moderate depression, the difference in symptom reduction between these drugs and placebo is often clinically insignificant—sometimes less than two points on the Hamilton Depression Rating Scale, a margin that many experts argue is meaningless in practical terms.
Another glaring example is the class of drugs known as cholinesterase inhibitors, including donepezil (Aricept),